Data curation for drug therapies approved by the FDA in 2024 has been completed. A total of 50 drugs was approved, comprising 34 NDAs and 16 BLAs. Nearly all of the NDAs have relevant in vitro and clinical findings related to drug interactions, food effect, organ impairment studies, and PGx data. PBPK modeling and simulations were deemed sufficient for 9 drugs to support DDI assessment and label recommendations. Drug monographs are also available, summarizing key DDI results, characteristics, QT information, and PK data.
The full list of NDA/BLAs entered into DIDB last year can be accessed at: https://didb.druginteractionsolutions.org/resources/all-ndas/
Do not hesitate to contact us with comments or suggestions.